Study EMPEROR-Reduced: design, results and implications for clinical practice

Česká verzia

Authors: Zbynek Schroner
Authors place of work: SchronerMED s. r. o., Košice
Published in the journal: Diab Obez 2020; 20(40): 114-116
Category: Clinical studies

Summary

The aim of EMPEROR -Reduced (Empagliflozin in Chronic Heart Failure With a Reduced Ejection Fraction, With and Without Diabetes) study was to examine the efficacy and safety of empagliflozin 10 mg in comparison with placebo, in addition to recommended therapy in patients with heart failure with a reduced ejection fraction. The primary composite outcome was death from cardiovascular causes or hospitalisation for heart failure. Empagliflozin leads to significant reduction of 25 % in the risk of primary outcome. The effect of empagliflozin on the primary outcome was consistent in patients regardless on the presence or absence of diabetes. There was 30 % reduction of separate hospitalisation for heart failure in the empagliflozin group vs placebo. Among patients receiving empagliflozin, there was an increased rate of genital infection in comparison with placebo, otherwise it was safe and well tolerated.

Keywords:

empagliflozin – EMPEROR-Reduced – heart failure – type 2 diabetes mellitus

Zdroje

Packer M, Anker SD, Butler G et al. Cardiovascular and renal outcomes with empagliflozin in heart falure. N Engl J Med 2020; 383(15): 1413–1424. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2022190>.
Butler G Packer M, Anker SD et al. Empagliflozin for the treatment of chronic heart failure and a reduced ejection fraction in patients with and without diabetes: new results of the EMPEROR-Reduced trial. EASD 2020. Dostupné z WWW: <https://www.easdhighlights.com/2020/articles/04-the-emperor-reduced-trial-for-empagliflozin/read?switch_language=en>.
McMurray JJ, Solomon SD, Inzucchi SE et al. Dapagliflozin in patients with heart failure and reduced ejecion fraction. N Engl J Med 2019; 381(21): 1995–2008. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1911303>.
Buse JB, Wexler D, Tsapas A et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2020; 43(2): 487–493. Dostupné z DOI: <http://dx.doi.org/10.2337/dci19–0066>.
Grant PJ, Cosentino F. The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen. Eur Heart J 2019; 40(39): 3215–3217. Dostupné z DOI: <http://doi: 10.1093/eurheartj/ehz687>.